Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Nov 8;115(11):1243-1245.
doi: 10.1093/jnci/djad129.

Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?

Minna K Lee  1 , Mark E Robson  2
Affiliations
Comment

Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?

Minna K Lee et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

M.L. has no disclosures. M.R. reports personal fees from Research to Practice, Intellisphere, myMedEd, Change Healthcare, and Physician’s Education Resources; consulting for Artios Pharma (uncompensated), AstraZeneca (uncompensated), Daiichi-Sankyo (uncompensated), Epic Sciences (uncompensated), Merck (uncompensated), Pfizer (uncompensated), Tempus Labs (uncompensated), and Zenith Pharma (uncompensated); grants from AstraZeneca (institution, clinical trials), Merck (institution, clinical trial), Pfizer (institution, clinical trial); and other support from AstraZeneca (editorial services) and Pfizer (editorial services), all outside the submitted work.

M.R., who is a JNCI associate editor and co-author on this paper, was not involved in the editorial review or decision to publish the manuscript.

Comment on

  • Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.
    van Barele M, Akdeniz D, Heemskerk-Gerritsen BAM; Genepso; Andrieu N, Noguès C; HEBON; van Asperen CJ, Wevers M, Ausems MGEM, de Bock GH, Dommering CJ, Gómez-García EB, van Leeuwen FE, Mooij TM; EMBRACE; Easton DF, Antoniou AC, Evans DG, Izatt L, Tischkowitz M, Frost D, Brewer C, Olah E, Simard J, Singer CF, Thomassen M, Kast K, Rhiem K, Engel C, de la Hoya M, Foretová L, Jakubowska A, Jager A, Sattler MGA, Schmidt MK, Hooning MJ. van Barele M, et al. J Natl Cancer Inst. 2023 Nov 8;115(11):1318-1328. doi: 10.1093/jnci/djad116. J Natl Cancer Inst. 2023. PMID: 37369040 Free PMC article.

References

    1. Tung NM, Boughey JC, Pierce LJ, et al.Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. J Clin Oncol. 2020;38(18):2080-2106. doi:10.1200/JCO.20.00299. - DOI - PubMed
    1. Robson ME. Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. Cancer Control. 2002;9(6):457-465. doi:10.1177/107327480200900602. - DOI - PubMed
    1. Zhao W, Wiese C, Kwon Y, Hromas R, Sung P.. The BRCA tumor suppressor network in chromosome damage repair by homologous recombination. Annu Rev Biochem. 2019;88:221-245. doi:10.1146/annurev-biochem-013118-111058. - DOI - PMC - PubMed
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, et al.; BRCA1 and BRCA2 Cohort Consortium. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112. - DOI - PubMed
    1. Metcalfe K, Gershman S, Lynch HT, et al.Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9):1384-1392. doi:10.1038/bjc.2011.120. - DOI - PMC - PubMed

Publication types

LinkOut - more resources